Concepedia

Publication | Closed Access

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

DOI

180

Citations

7

References

1992

Year

Gisele Sarosy, Elise C. Kohn, David A. Stone, M.L. Rothenberg, J Jacob, Debra O. Adamo, Frederick P. Ognibene, Robert E. Cunnion, E Reed
Journal of Clinical Oncology

Abstract

Taxol can be safely administered in doses up to 250 mg/m2 with G-CSF support, which may make it possible to study taxol dose intensification.

References

YearCitations

Page 1